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Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance <p>Comprehensive multi-tissue gene-expression analysis uncovered complex multiple signaling pathways that mediate the molecular  actions of TRβ mutants <it>in vivo</it>. In particular, the T3-independent mutant-dependent genomic response unveiled the contribution  of a novel 'change-of-function' of TRb mutants to the pathogenesis of RTH. Thus, the molecular actions of TRβ mutants are more complex  than previously envisioned.</p>
Abstract
Background:  Resistance to thyroid hormone (RTH) is caused by mutations of the thyroid
hormone receptor β (TRβ) gene. To understand the transcriptional program underlying TRβ
mutant-induced phenotypic expression of RTH, cDNA microarrays were used to profile the
expression of 11,500 genes in a mouse model of human RTH.
Results: We analyzed transcript levels in cerebellum, heart and white adipose tissue from a knock-
in mouse (TRβPV/PV mouse) that harbors a human mutation (referred to as PV) and faithfully
reproduces human RTH. Because TRβPV/PV mice have elevated thyroid hormone (T3), to define T3-
responsive genes in the context of normal TRβ, we also analyzed T3 effects in hyperthyroid wild-
type gender-matched littermates. Microarray analysis revealed 163 genes responsive to T3
treatment and 187 genes differentially expressed between TRβPV/PV mice and wild-type littermates.
Both the magnitude and gene make-up of the transcriptional response varied widely across tissues
and conditions. We identified genes modulated in T3-dependent PV-independent, T3- and PV-
dependent, and T3-independent PV-dependent pathways that illuminated the biological
consequences of PV action in vivo. Most T3-responsive genes that were dysregulated in the heart
and white adipose tissue of TRβPV/PV mice were repressed in T3-treated wild-type mice and
upregulated in TRβPV/PV mice, suggesting the inappropriate activation of T3-suppressed genes in
RTH.
Conclusions: Comprehensive multi-tissue gene-expression analysis uncovered complex multiple
signaling pathways that mediate the molecular actions of TRβ mutants in vivo. In particular, the T3-
independent mutant-dependent genomic response unveiled the contribution of a novel 'change-of-
function' of TRβ mutants to the pathogenesis of RTH. Thus, the molecular actions of TRβ mutants
are more complex than previously envisioned.
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Background
Thyroid hormone (T3) regulates growth, development and
differentiation. These actions are mediated by high-affinity
thyroid hormone receptors (TRs) that bind T3 and localize to
the nucleus, where they regulate transcription of target genes.
Four T3-binding TR isoforms, β1, β2, β3 and α1, are derived
from two TR genes (β and α genes) by alternative splicing of
the primary transcripts [1-3]. The expression of these TR iso-
forms is tissue dependent and developmentally regulated
[1,2,4]. As transcription factors, the TRs regulate gene expres-
sion by binding thyroid-hormone response elements (TREs)
in the regulatory domains of target genes which can confer
specificity for TR isoforms [5]. The transcriptional activity of
the TRs is also modulated by a host of co-repressors and co-
activators [6].
Mutations in TRβ that affect its ability to bind T3 or interact
with co-repressors results in the syndrome known as resist-
ance to thyroid hormone (RTH) [7-9]. RTH is a dominantly
inherited abnormality that manifests as an impaired sensitiv-
ity of thyroid hormone-responsive tissues to circulating T3
[7,9]. Clinical diagnosis of RTH typically recognizes elevated
levels of thyroid hormone associated with nonsuppressible
thyroid-stimulating hormone (TSH) [7,9]. The clinical pres-
entation of the disease is hypothyroidism, with symptoms
such as delayed growth, cognitive dysfunction, and hypercho-
lesterolemia, and, concurrently, signs consistent with hyper-
thyroidism, including tachycardia, weight loss, attention
deficit-hyperactivity disorder and advanced bone age. The
hypothyroid-like effects are presumably the consequence of
mutant TRβ interference with, or inhibition of, normal T3 sig-
naling pathways, whereas the signs reflective of hyperthy-
roidism result from the elevated T3 driving the activity of the
TRα1 isoform [10].
To investigate the physiological consequences of a mutant β
receptor in the germline, a mouse model expressing a TRβ
mutant was created using homologous recombination and
the Cre/loxP system [11]. The targeted TRβ mutation
(referred to as PV) was the same as that from a patient with
severe RTH whose symptoms included elevated T3 and T4,
nonsuppressible TSH, goiter, tachycardia and short stature
[12]. The PV mutant was shown in vitro to lack both T3-bind-
ing activity and transcriptional capacity and to strongly inter-
fere with the transcriptional activity of normal TRs [12]. The
PV mutant was found expressed in all mouse T3-target tissues
examined, including cerebrum, cerebellum, pituitary, liver,
brown and white adipocytes, heart, muscle, lung, spleen and
kidney [11]. TRβPV mice exhibited goiter, delayed bone devel-
opment, impaired weight gain, hearing defects and hypercho-
lesterolemia, all of which are reminiscent of the clinical
presentation of RTH in humans [11,13,14].
The availability of this mouse model provides an extraordi-
nary opportunity to understand the molecular actions of TRβ
mutants and to elucidate the affected cellular pathways in
vivo. To this end, we applied high-density cDNA microarrays
to identify PV-affected genes in the heart, cerebellum and
white adipose tissue (WAT) of TRβPV/PV mice. Concurrently,
we analyzed the expression profiles of wild-type littermates
treated with T3 to uncover T3-responsive genes in the context
of normal TRβ in a model of pharmacologic hyperthyroidism.
Across the three tissues analyzed, we identified (by twofold
change or more) 163 distinct genes responsive to T3 treat-
ment and 187 genes differentially expressed between TRβPV/
PV mice and wild-type littermates.
The expression patterns of these genes showed a diverse tran-
scriptional response comprising genes with tissue-specific
expression and genes with similar or contrasting expression
in multiple tissues. Category analysis of expression patterns
identified genes that were modulated by T3-dependent PV-
independent, T3- and PV-dependent, and T3-independent
PV-dependent mechanisms. Intra-tissue expression analysis
provided a biological glimpse of the adverse effects of PV in a
tissue-dependent manner. Finally, hierarchical clustering of
multi-tissue gene-expression patterns revealed evidence of
discrete biological pathways including immune response,
lipogenesis and cell-cycle inhibition that are modulated in
multiple tissues of hyperthyroid and T3-resistant TRβPV/PV
mice. These findings provide a molecular framework for
understanding the variability in tissue sensitivity of RTH and
provide insight into signaling pathways of mutant TRβ  in
vivo.
Results
Experimental design
RTH, caused by mutation of the TRβ gene, is the consequence
of abnormal transcription of thyroid-hormone-responsive
genes in T3 target tissues. Using a mouse cDNA microarray
containing 11,500 gene probes (representing over 10,000
unique named and unnamed expressed sequence tags
(ESTs)), we profiled gene-expression patterns in mouse mod-
els of hyperthyroidism and RTH to reveal T3-responsive
(hyperthyroid-associated) and mutant PV-dysregulated
genes. The three T3-target tissues profiled in this study were
the cerebellum, heart and WAT, all of which are important
T3-target tissues in which T3-responsive genes have yet to be
comprehensively analyzed. The experimental comparisons in
this study included: wild-type mice versus TRβPV/PV litterma-
tes (the RTH group); wild-type mice injected with T3 versus
those receiving saline injection only (the iT3 group); and
wild-type mice versus a second set of wild-type animals
selected in the same way (the control group).
In the RTH experiments, we identified changes in gene
expression resulting from the in vivo action of PV and/or ele-
vated T3 characteristic of clinical RTH. The iT3 experiments
revealed genes that are responsive to increased levels of T3 in
pharmacologic hyperthyroidism. These experiments allowed
us to analyze the expression profiles in RTH that are thehttp://genomebiology.com/2004/5/5/R31 Genome Biology 2004,     Volume 5, Issue 5, Article R31       Miller et al. R31.3
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Genome Biology 2004, 5:R31
effects due to the increased levels of circulating thyroid hor-
mone and thus to understand which TR-subtype-dependent
transcriptional mechanisms govern gene expression. The
purpose of the control group was to identify genes that natu-
rally fluctuate as the result of normal inter-animal differences
[15]. Genes identified as differentially expressed in the con-
trol group were subsequently censored in a tissue-dependent
manner. For each experimental comparison, replicate micro-
array hybridizations were performed with reciprocal labeling
(dye-swapping) to minimize technical noise (see Materials
and methods).
Identification and characterization of T3-responsive 
genes
Differentially expressed genes (outliers) were selected based
on the 2.0r criterion whereby the fold change detected on
each of two reciprocally labeled arrays (r designation) was
greater than twofold (up or down, but in a reciprocal manner)
in at least one experimental comparison. The average expres-
sion ratios were calculated as described (see Materials and
methods) and are used herein as the expression ratio meas-
urements. To evaluate the probe-level reproducibility of the
microarray data, we examined the variability of the expres-
sion ratios for all genes represented by multiple probes on the
array and identified as outliers in multiple experimental com-
parisons (see Additional data file 1). A high degree of expres-
sion-ratio reproducibility was observed, even for changes less
than twofold, lending confidence to our microarray results
and outlier selection criteria. Notably, the 2.0r criterion was
applied to achieve a high level of stringency in detecting gene
outliers. However, this approach precludes the identification
of genes that are differentially expressed at levels below 2.0r
detection (for example, 1.9-fold change) thus obscuring the
distinction of tissue-specific outliers and excluding poten-
tially important distinguishing gene cassettes. In the light of
this, we compiled a dataset that lists all genes passing the 2.0r
criterion in at least one experimental comparison and identi-
fies all instances (in other experimental comparisons) where
these genes pass a less stringent threshold of 1.2r (see Addi-
tional data files 2 and 3). Thus, a transcript that shows a min-
imum change of twofold in one comparison can be
subsequently screened for smaller changes, or categorized as
having virtually no change in expression (that is, less than 1.2-
fold), in other comparisons.
To gauge the accuracy of our methodology in correctly identi-
fying T3-regulated genes, we searched for the 2.0r outliers
across the three tissues for genes or gene products previously
known to be regulated by T3. Representative genes are listed
in Additional data file 4 and include 10 genes whose mRNA
expression have been reported previously to be regulated by
T3 and five genes that are known to be affected by T3 at the
protein level. Two genes categorized as effectors are also
listed. These include transthyretin (Ttr), a high-affinity
serum thyroid-hormone-binding protein that transports thy-
roid hormone to target tissues, thus facilitating thyroid
hor-mone distribution [16], and the retinoid X receptor α
(Rxra), a member of the nuclear receptor superfamily that
heterodimerizes with TRs and modulates the transcriptional
activity of TRs [1].
To confirm the validity of the microarray results, four outliers
(two up- and two downregulated genes) each were selected
from the cerebellum and WAT for the determination of
mRNA expression by reverse transcription PCR (RT-PCR)
analysis. The patterns and fold changes in the expression of
adenomatous polyposis coli (APC), somatostatin, carbonic
anhydrase 4 and tenascin C in the cerebellum (Figure 1a) and
those of lysyl oxidase, carbonic anhydrase 4, enolase 3β and
creatine kinase in the WAT (Figure 1b) determined by RT-
PCR were all consistent with those obtained by the arrays.
Even though there was a slight variability in the magnitude of
the response between the two methods, the patterns of
response were in concordance.
Concordance of gene expression determined by microarrays and RT-PCR Figure 1
Concordance of gene expression determined by microarrays and RT-PCR. 
Expression ratios of representative genes in (a) cerebellum and (b) white 
adipose tissue identified as outliers by microarrays were determined by 
RT-PCR as described in Materials and methods. The solid bars represent 
the data from the microarrays and the open bars are from the RT-PCR 
(mean ± SEM, n = 3).
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Variability in tissue-dependent transcriptional 
response in mice treated with T3 and in TRβPV/PV mice
The number of genes that are differentially expressed in a tis-
sue following T3 treatment can be viewed as an indirect meas-
ure of pharmacodynamic effect. For example, tissues that
show a large number of gene outliers in response to T3 treat-
ment would suggest higher sensitivity to T3 than tissues
responding with a few outliers. This has been found to be true
for chemotherapeutic effects, and for estrogen responsive-
ness [17]. This principle can therefore be used as a metric for
assessing tissue sensitivity to T3 treatment or the PV mutant.
A breakdown of the number of 2.0r outliers identified in each
tissue of each comparison is shown in Table 1. The number of
outliers varied markedly between tissue types. For example,
in the WAT, 58 and 172 outliers were detected in each of the
comparisons (that is, with versus without T3 treatment (iT3
mice) and wild-type versus TRβPV/PV  mice (RTH group),
respectively), whereas in the cerebellum only 21 were found
in the iT3 group and none was found in the RTH group. In the
heart, 98 outliers were found in the iT3 group and 17 in the
RTH group. Therefore, adult cerebellum appears to be the tis-
sue least sensitive to T3 treatment and the action of PV,
whereas the heart is a particularly responsive tissue in our
model of hyperthyroidism, and white adipose is the most sen-
sitive tissue in our model of RTH.
Intriguingly, the distribution patterns of up- and downregu-
lated genes showed a consistent trend in two tissues that dis-
tinguished the hyperthyroid and RTH conditions (Table 1). In
both the heart and WAT, the predominant response to T3
administration (that is, iT3 group) was mostly downregula-
tion of expression (71% and 76% of the outliers, respectively).
By contrast, in the TRβPV/PV mice we observed higher propor-
tions of transcriptionally induced genes. In the heart and
WAT of RTH animals, 65% and 53% of outliers, respectively,
were upregulated genes. Together, these data support the
intriguing view that the hyperthyroid phenotype is largely
mediated through T3-induced suppression of gene expres-
sion, whereas RTH is underscored by an inappropriate
increase in transcriptional activity in T3 target tissues. These
data strongly suggest that target-tissue response to T3 admin-
istration and the RTH genotype are distinctly different.
To further characterize the target-tissue transcriptional
response, we analyzed each tissue for its degree of transcrip-
tional uniqueness. We found that in the T3-treated mice, 24%
(5/21), 24% (24/98), and 22% (13/58) of outliers in the cere-
bellum, heart and WAT, respectively, were tissue specific
(that is, differentially expressed by twofold or more in only
one tissue, and not more than 1.2-fold in any other tissue). In
the RTH mice, 0% (0/0), 53% (9/17), and 47% (81/172) of
outliers in the cerebellum, heart and WAT, respectively, were
detected in only one tissue type (data not shown). These
observations reveal a considerable degree of transcriptional
specificity that is dependent on tissue type, consistent with
the notion that the transcriptional behavior of TRs depends
on the molecular composition of the cell type with respect to
the availability and levels of cofactors that modulate TR tran-
scriptional activity [14,18].
Gene classification by transcriptional response
The pathological hallmark of RTH is elevated thyroid hor-
mone associated with nonsuppressible TSH. Even though the
phenotypic consequences of elevated thyroid hormone in
RTH patients are known, it is not clear what genes mediate
the phenotypes. Furthermore, RTH may manifest as hyper-
thyroidism in one tissue, and, simultaneously, hypothy-
roidism in another [9]. Dissecting this variable phenotype
into the hyperthyroid and non-hyperthyroid components at
the molecular level requires a comprehensive knowledge of
the hyperthyroid-related genes in each tissue, and the expres-
sion patterns of these genes in the context of RTH. Therefore,
we performed a tissue-by-tissue analysis cross-comparing the
genomic effects of iT3 and RTH to segregate genes according
to cognate response patterns.
Four categories of response patterns were discerned and
labeled A, B, C and D, as shown in Figure 2. The outliers in
category A (brown bars in Figure 2) are the genes that showed
the same directionality of change in both T3-treated and
TRβPV/PV mice (that is, up in both or down in both). That the
mutant TRβ does not alter the transcriptional response of
genes responsive to elevated T3 suggests their potential
involvement in the hyperthyroid phenotype. As shown in Fig-
ure 2, two genes were identified in the cerebellum, five in the
heart, and 39 in the WAT.
Table 1
Comparison of the numbers of 2.0r outliers detected in iT3 and RTH tissues
Cerebellum Heart White adipose
Condition Total Up-
regulated
Down-
regulated
Total Up-
regulated
Down-
regulated
Total Up-
regulated
Down-
regulated
iT3 21 18 (86%) 3 (14%) 98 28 (29%) 70 (71%) 58 14 (24%) 44 (76%)
RTH 0 0 0 17 11 (65%) 6 (35%) 172 92 (53%) 80 (47%)http://genomebiology.com/2004/5/5/R31 Genome Biology 2004,     Volume 5, Issue 5, Article R31       Miller et al. R31.5
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Category B (orange bars) includes the outlier genes that
showed reversed patterns of change between iT3 and RTH
mice (that is, up in iT3 but down in RTH, or vice versa). Pre-
sumably, these genes, which are responsive to increased T3
levels (in iT3 mice), are expressed in the opposite direction in
TRβPV/PV mice as a consequence of mutant TRβ activity. One
such outlier was identified in the cerebellum, 25 in the heart,
and 33 in the WAT. Interestingly, 84% (21/25) and 79% (26/
33) of these genes in the heart and WAT, respectively, were
downregulated in response to T3 treatment and concomi-
tantly upregulated in RTH, further supporting the view that
an important molecular aspect of RTH is the abnormal
expression of otherwise T3-repressed genes. A mechanistic
explanation is that these category B genes are regulated by T3
mostly (or exclusively) through the TRβ receptor.
The majority of the outliers identified in this study, however,
were found exclusively in either iT3 (category C, blue bars) or
RTH (category D, pink bars) mice. Genes in category C
showed a greater than twofold change in iT3 mice and less
than 1.2-fold change in RTH mice. Therefore, these genes
were responsive to increased T3 in the iT3 group but insensi-
tive to elevated T3 in the presence of the mutant TRβ recep-
tor. In this category, we identified 18, 72 and 27 such genes in
the cerebellum, heart and WAT, respectively. Conversely, the
outliers in category D were detected in RTH but not in the iT3
g r o u p .  C o m p a r e d  w i t h  c a t e g o r y  C ,  a  r e l a t i v e l y  s m a l l e r
number of such genes were identified in the cerebellum (0
genes) and the heart (3 genes), but a significantly larger
number of outliers (116 genes) were detected in the WAT.
Taken together, these data show that the expression patterns
of iT3 and RTH responsive genes are not only tissue-depend-
ent, but also can differ markedly between the hyperthyroid
and RTH states within the same tissue.
Hierarchical clustering identifies biological pathways 
associated with hyperthyroid (iT3) and RTH 
phenotypes
Hierarchical clustering of gene-expression patterns can pro-
vide a robust, composite view of cellular pathways operative
in a biological system as evidenced by the coordinate expres-
sion of functionally related genes. To gain insight into the
pathways most perturbed in our models, we analyzed the
expression patterns of genes differentially expressed in one or
more tissues of hyperthyroid (iT3) or RTH mice. In Figure 3,
the expression patterns of these genes were hierarchically
clustered and the functionality of genes within clusters was
analyzed using Gene Ontology (GO) terms. We identified
three gene clusters with ostensible biological implications: A,
an immunity cluster: B, a lipogenesis cluster; and C, a cell
cycle/growth inhibitory cluster. The immunity cluster is
largely characterized by a trans-tissue downregulation of
genes involved in immune response pathways or immune-cell
biology (A, black bar, Figure 3). These genes are repressed in
one or more tissues of T3-treated and/or TRβPV/PV mice and
are all consistently downregulated in the WAT of TRβPV/PV
mice. These include several HLA class II antigen genes (H2-
Ab1, H2-Aa, and H2-Eb1), chemotactic factor genes (Ccl22
and  Ccl19), and genes involved in lymphocyte activation
(Lcp2, Ptprcap and Ms4a1) and adherence (Sell), strongly
suggesting an immunomodulatory response in tissues of both
hyperthyroid and TRβPV/PV mice.
In the lipogenesis cluster (B, blue bar, Figure 2), six of eight
genes have clearly defined roles in fatty-acid and lipid metab-
olism and include Fasn, Acly, Gpd1, Elovl6, Slc25a1, and a
gene named 'similar to acetyl-coenzyme A carboxylase, clone
IMAGE: 5151139' which has 99% identity at the protein level
with rat acetyl-coenzyme A carboxylase. These genes are con-
sistently repressed by T3 in the heart and WAT, and
expressed at reduced levels in the WAT of TRβPV/PV mice, with
half of the genes being induced in the heart of TRβPV/PV mice
(blue bar, Figure 3). These patterns are consistent with the
negative regulation of lipogenesis in the hyperthyroid heart
Category analysis of transcriptional response patterns Figure 2
Category analysis of transcriptional response patterns. Intra-tissue 
expression patterns of genes showing twofold change or more in iT3 and/
or RTH (PV) mice are shown. Red indicates higher expression levels in iT3 
or RTH mice; green indicates lower expression in iT3 or RTH mice. Black 
indicates less than 1.2-fold change. The level of color saturation reflects 
the magnitude of the expression ratio. The number of genes found in each 
category is shown.
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a n d  W A T .  I n  R T H  m i c e  t h i s  s u g g e s t s  s u p p r e s s i o n  o f
lipogenesis in the WAT with simultaneous increase in lipo-
genesis in the heart.
The smaller cell-cycle/growth-inhibitory cluster is composed
of several genes known to inhibit growth or cell-cycle progres-
sion or promote apoptosis (C, pink bars, Figure 3). These
genes include Bnip3,  Gadd45a  and  Cdkn1a  (p21). Shown
adjacent to this gene cluster is the similarly expressed gene,
APC (adenomatous polyposis coli), whose expression is also
associated with growth inhibition (that is, via suppression of
the Wnt signaling pathway which we recently showed to be
negatively regulated by T3 [19]). A hallmark of these genes
(with the exception of Gadd45a) is increased expression in all
three tissues of the hyperthyroid mouse. Notably, p21 is also
upregulated in the heart and WAT of TRβPV/PV mice, suggest-
ing its induction in these tissues in response to high circulat-
ing T3. These findings raise the possibility that induction of
growth-inhibitory mechanisms in multiple T3 target tissues
may contribute to the pathogenesis of RTH.
Gene-expression patterns in hyperthyroid and RTH 
hearts are distinct
The heart is highly sensitive to thyroid hormone and the pri-
mary mode of T3 action is a direct influence on cardiac gene
expression [20]. Increased heart rate (tachycardia) and
myocardial contractility are clinical features common to both
hyperthyroidism and RTH [21,22]. As the predominant TR
isoform in the heart is TRα1, and RTH patients have normal
expression levels of TRα1 together with elevated thyroid hor-
mone, it has been postulated that the cardiac effects common
to both hyperthyroidism and RTH are mediated by TRα1 sig-
naling [20,23]. To examine this hypothesis at the molecular
level, we compared the genomic effects of induced
Hierarchical clustering of differentially expressed genes identifies gene clusters with biological associations Figure 3
Hierarchical clustering of differentially expressed genes identifies gene clusters with biological associations. Gene-expression patterns are shown in rows; 
tissue profiles in columns. Degree of color saturation reflects the magnitude of the expression ratio. Note that for optimal clustering, the expression data 
for each individual dye-swap experiment was used (see key for directionality of expression via color pairs). The black bar at the right side of the main array 
indicates the immunity cluster, the blue bar the lipogenesis cluster, and purple bars the cell-cycle/growth-inhibitor genes.
618271 histocompatibility 2, class II antigen A, beta 1
574303 lymphocyte cytosolic protein 2
571328 protein tyrosine phosphatase, receptor type, C polypeptide-associated protein
621878 selectin, lymphocyte
747378 histocompatibility 2, class II antigen A, alpha
851752 chemokine C-C motif ligand 22
637849 histocompatibility 2, Q region locus 7
616709 membrane-spanning 4-domains, subfamily A, member 1
596470 CD79B antigen
737803 histocompatibility 2, class II antigen E beta
832043 chemokine C-C motif ligand 19
693560 ELOVL family member 6, elongation of long chain fatty acids yeast
571633 solute carrier family 25 mitochondrial carrier; citrate transporter, member 1
576881 fatty acid synthase
439735 Mus musculus, Similar to acetyl-coenzyme A carboxylase, clone 5151139, mRNA
570675 glycerol-3-phosphate dehydrogenase 1 soluble
352146 ATP citrate lyase
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586330 adenomatosis polyposis coli
463388 BCL2/adenovirus E1B 19kDa-interacting protein 1, NIP3
446036 growth arrest and DNA-damage-inducible 45 alpha
419146 cyclin-dependent kinase inhibitor 1A P21
>2 1.2 >2 1.2
Fold change:
= up in iT3, up in RTH (PV)
= down in iT3, down in RTH (PV)
764497 interleukin 2 receptor, gamma chain
Repression
Induction
A
A
B
C
B
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Table 2
Gene-expression patterns in iT3 and RTH hearts are distinct
Heart
Clone ID and 
UniGene name
iT3 RTH Muscle related Calcium ion 
binding
ATP binding and 
electron transport
Mitochondrion 
related
481408 cytochrome 
c oxidase, subunit 
VIIIa
2.78↓ NC ET MR
439199 
aminolevulinic acid 
synthase 2, 
erythroid
3.33↓ NC ET MR
571367 BCL2/
adenovirus E1B 
19kDa-interacting 
protein 1, NIP3
3.89↑ 1.27↓ MR
350881 RIKEN 
cDNA 
5730438N18 gene
3.73↑ NC MR
482847 uncoupling 
protein 3, 
mitochondrial
3.69↑ NC MR
318951 malonyl-
CoA decarboxylase
2.19↑ NC MR
920211 solute 
carrier family 40 
(iron-regulated 
transporter), 
member 1
2.13↑ NC MR
571633 solute 
carrier family 25 
(mitochondrial 
carrier; citrate 
transporter), 
member 1
3.03↓ 1.38↑ MR
318134 
translocator of 
inner mitochondrial 
membrane a
3.13↓ NC MR
481469 [Mrps18b] 4.00↓ NC MR
423605 aldehyde 
dehydrogenase 1 
family, member B1
3.45↓ NC ATPB MR
352146 ATP citrate 
lyase
2.78↓ NC ATPB
570675 glycerol-3-
phosphate 
dehydrogenase 1 
(soluble)
3.33↓ NC ATPB
554335 Rous 
sarcoma oncogene
5.00↓ NC ATPB
1196244 
lymphocyte protein 
tyrosine kinase
7.69↓ NC ATPBR31.8 Genome Biology 2004,     Volume 5, Issue 5, Article R31       Miller et al. http://genomebiology.com/2004/5/5/R31
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hyperthyroidism and RTH in the mouse heart. In total, we
identified 105 gene outliers that showed twofold change or
more in the iT3 or RTH groups (see Additional data file 5).
Notably, this list does not include several genes previously
implicated in T3-mediated cardiac effects such as those for
the α- and β-myosin heavy chains, SERCA2 and HCN2, as
they were not represented on our microarray. To focus on the
set of most relevant genes in our list, we used the GO database
of biological and functional gene classifications [24] to define
genes known or expected to have a role in cardiac muscle
contraction.
Hence, we classified 23 genes into one or more of the follow-
ing categories (Table 2): muscle-related; calcium-ion binding
(calcium-ion release and retrieval is central to muscle con-
traction and relaxation); ATP binding and electron transport
(ATP is the immediate source of energy that powers muscle
contraction); mitochondrion related (cardiac muscle has the
richest supply of mitochondria and T3 directly boosts energy
metabolism in mitochondria via gene transcription).
We hypothesized that the expression patterns of these genes
would be similar in the iT3 and RTH hearts as they are pre-
sumably regulated by TRα1 and responsive in the context of
elevated T3. Surprisingly, however, this analysis indicated
that the iT3 and RTH hearts are molecularly distinct. Of the
23 genes identified, none showed the same or similar
response patterns. Eighteen genes, which ranged from four-
fold induction to 20-fold suppression in the iT3 heart, showed
less than a 1.2-fold change in RTH (that is, category C genes,
Figure 2). Moreover, the remaining five genes were expressed
in opposite directions (that is, category B genes, Figure 2).
These include the gene for myosin light chain, regulatory A (>
20-fold repressed in iT3 and > 6.6-fold increased in RTH) and
the sarcolipin gene (> 4.8-fold repressed in iT3 and > 3.6-fold
increased in RTH).
This expression pattern trend was also apparent in the
remaining 82 non-muscle-contraction-related outliers (see
Additional data file 5). Of these genes, 54 showed from 2- to
11-fold change in response to T3 injection and concurrently
no change in RTH mice, while only three showed a greater
then twofold change in RTH with no concurrent change in iT3
mice. Of the 25 genes in this group that showed change in
both iT3 and RTH mice, only five showed change in the same
direction (that is, candidates for TRα1-dependent transcrip-
tion, category A genes, Figure 2), whereas the remaining 20
genes showed opposing expression patterns. Such marked
differences between iT3 and RTH hearts suggest a greater
role for TRβ in the heart than previously envisioned, or inter-
ference of TRα1-mediated transcription by TRβPV or its
downstream effects.
Functional interpretation of expression profiles in the 
WAT of RTH mice
Thyroid hormone is an important regulator of adipose tissue
development and metabolism. T3 is thought to exert its
effects on fat cells through transcriptional regulation by both
α1 and β receptors [25]. Although a number of T3 target genes
in adipose tissues have been described [26,27], little is known
of the transcriptional response of adipocyte T3 target genes in
RTH. Accordingly, we compared WAT expression patterns in
the iT3 and RTH groups. In total, we identified 215 genes that
showed twofold change or more in either iT3 or RTH (see
349954 myosin 
heavy chain 11, 
smooth muscle
2.04↓ NC MC ATPB
318692 sarcolipin 4.76↓ 3.58↑ MC
604414 (vimentin) 2.56↓ 2.27↑ MD
890932 calcium 
channel, voltage-
dependent, alpha2/
delta subunit 1
2.10↑ NC MC CCA
479382 myosin light 
chain, regulatory A
20.0↓ 6.64↑ MC CIB
354796 fibulin 1 2.38↓ NC CIB
472672 S100 
calcium binding 
protein A10 
(calpactin)
2.70↓ NC CIB
335868 
(angiotensinogen)
3.13↓ NC CIB
↑ indicates fold of activation; ↓ indicates fold of repression; NC indicates no changes (< 1.2-fold). MC, muscle contraction; MD, muscle development; 
CCA, calcium channel activity; CIB, calcium ion binding; ATPB, ATP binding; ET, electron transport; MR, mitochondrion related.
Table 2 (Continued)
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Table 3
Genes involved in cell adhesion, lipogenesis and immune cell biology are modulated in white adipose tissue of RTH and iT3 mice
WAT
Clone ID and UniGene name iT3 RTH
Cell Communication: cell adhesion
484261 : keratin complex 1, acidic, gene 13 NC 2.36↑
335736 : keratin complex 2, basic, gene 6a NC 2.73↑
464060 : keratin complex 1, acidic, gene 19 NC 3.54↑
420709 : RIKEN cDNA 5730453H04 gene NC 14.02↑
762299 : CEA-related cell adhesion molecule 1 NC 4.87↑
776133 : cadherin 1 NC 6.20↑
719965 : desmocollin 2 NC 2.79↑
761578 : desmoglein 2 1.49↓ 3.30↑
Metabolism: lipogenesis
570675 : glycerol-3-phosphate dehydrogenase 1 
(soluble)
2.33↓ 1.49↓
352146 : ATP citrate lyase 4.17↓ 2.94↓
439735 : Mus musculus, Similar to acetyl-
coenzyme A carboxylase, clone 5151139
2.13↓ 2.38↓
576881 : fatty acid synthase 2.94↓ 3.13↓
693560 : ELOVL family member 6, elongation of 
long chain fatty acids (yeast)
2.38↓ 2.22↓
578436 : phosphogluconate dehydrogenase 1.72↓ 3.03↓
949810 : hexose-6-phosphate dehydrogenase 
(glucose 1-dehydrogenase)
2.50↓
Response to external stimuli: immune cell 
biology
620268 : CD53 antigen 2.27↓ 2.86↓
621878 : selectin, lymphocyte 1.33↓ 2.44↓
618271 : histocompatibility 2, class II antigen A, 
beta 1
1.30↓ 3.02↓
747378 : histocompatibility 2, class II antigen A, 
alpha
1.43↓ 4.55↓
597433 : chemokine (C-X-C motif) ligand 13 1.27↓ 2.44↓
637849 : histocompatibility 2, Q region locus 7 NC 2.27↓
748587 : histocompatibility 2, class II antigen E 
beta
NC 2.70↓
575397 : chemokine (C-C motif) ligand 6 NC 2.13↓
851752 : chemokine (C-C motif) ligand 22 NC 3.02↓
832043 : chemokine (C-C motif) ligand 19 NC 2.78↓
596470 : CD79B antigen NC 2.94↓
↑ indicates fold of activation; ↓ indicates fold of repression; NC indicates no changes (< 1.2-fold).R31.10 Genome Biology 2004,     Volume 5, Issue 5, Article R31       Miller et al. http://genomebiology.com/2004/5/5/R31
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complete list in Additional data file 6). Assignment of the
named genes to GO biological processes (tier 3) revealed four
predominant biological classes: metabolism (n  = 45), cell
growth and maintenance (n = 24), cell communication (n =
24) and response to external stimuli (n = 16). The expression
patterns of genes in these categories provide a molecular
framework for interpreting the biological properties of WAT
in RTH. The length limitation of this paper permits only
description of a selected subset of genes. For example, within
the cell communication class we identified a number of genes
upregulated in RTH that are involved in cell-cell adhesion via
desmosomal junctions (Table 3). Desmosomes are major
intercellular adhesive junctions that provide strong mechani-
cal attachments between adjacent cells and are thought to
have a role in tissue morphogenesis and differentiation [28].
The adhesive core of the desmosome is comprised of proteins
of the cadherin family, namely desmogleins and desmocol-
lins. In the WAT of RTH animals, we observed a marked
upregulation of transcript levels of cadherin 1, desmoglein 2,
desmocollin 2 and the CEA-related cell adhesion molecule 1.
Desmosomes are anchored to intermediate filaments of kera-
tin in the cytoplasm. Here, we also observed increased tran-
script levels of the keratins Krt1-13, Krt1-19 and Krt2-6a. In
addition, the most highly upregulated transcript in the WAT
of RTH mice was a gene called 5730453H04Rik, which shares
95% identity (over 480 amino acids) with human desmo-
plakin, a major protein of desmosomes involved in the
anchoring of keratin intermediate filaments to desmosomes.
Within the metabolism class, we identified a number of genes
negatively regulated in the WAT of iT3 and RTH mice that are
directly involved in fatty-acid and lipid metabolism (Table 3).
These genes include those previously discovered in the
lipogenesis cluster of Figure 3 (that is, Fasn,  Acly,  Gpd1,
Elovl6, Slc25a1 and IMAGE: 5151139). Fatty-acid biosynthe-
sis is known to use large amounts of NADPH. As a conse-
quence, adipose tissue is known to express high levels of the
enzymes of the pentose phosphate pathway that generate
NADPH. Hexose-6-phosphate dehydrogenase and phos-
phogluconate dehydrogenase are two of the three major
enzymes in the pentose phosphate pathway, and both were
negatively regulated in the WAT of RTH animals.
The genes assigned to the class response to external stimuli
were, with only one exception, all downregulated in RTH ani-
mals, and in some cases, in iT3 mice (Table 3). All the genes
identified here are involved in immune response or immune-
cell biology and overlap with the previously identified immu-
nity-gene cluster of Figure 3. They include a number of chem-
okines, HLA antigens and other markers of lymphoid
lineages.
Taken together, these data suggest that the WAT of RTH mice
is characterized by increased cell-cell adhesion via desmo-
somal structures, and they recapitulate our initial findings of
a possible hyperthyroid-associated inhibition of lipogenesis
and a repression of immunomodulatory signaling.
Gene-expression patterns in the cerebellum of iT3 and 
RTH mice
Thyroid hormones are essential for normal brain develop-
ment and regulate neuronal proliferation, migration and syn-
aptogenesis in the cerebellum [29,30]. In our study, the
cerebellum was the least responsive tissue in both iT3 and
RTH mice, with only 13 genes and no genes, respectively
showing twofold or greater changes. The complete list of
genes with all GO classifications is shown in Additional data
file 7. The most highly induced gene (> threefold) in the cere-
bellum of T3-treated mice was the T3/T4-binding protein,
transthyretin, which is synthesized in large amounts in the
choroid plexus and is essential for the transport of thyroid
hormones from the blood to the brain [31]. Increased expres-
sion of transthyretin may represent a positive feedback mech-
anism for enhancing the effect of thyroid hormone in the
brain. mRNA for the retinoid X receptor (RXR) was also
induced more than threefold in response to T3. RXR is a
member of the nuclear receptor superfamily that het-
erodimerizes with TRs and modulates the transcriptional
activity of TRs [1]. T3-induced upregulation of RXR may
reflect the relative importance of TR-RXR heterodimeriza-
tion for T3 action in the cerebellum. Also induced by T3 treat-
ment were the genes APC and dickkopf homolog 3, which are
known or suspected antagonists of the Wnt signaling path-
way. Both T3 and Wnt pathways are known to have important
roles in neuronal growth and synaptogenesis [32-35]. We
recently presented genetic and biochemical evidence that thy-
roid hormone can inhibit the Wnt signaling pathway [19].
Thus, T3-mediated inhibition of Wnt signaling may be an
important aspect of cerebellar development and function.
The physiologic impact of the activation of these genes in
hyperthyroidism warrants further investigation.
Discussion
In this study, we sought to define the molecular basis of the
target-tissue phenotype for hereditary TRβ mutations using a
global gene expression approach. Specifically, we used
expression profiling as a complex readout for the in vivo
actions of T3 and PV in target tissues. The animal model was
a murine line with the TRβ disrupted in the identical manner
as found in the human condition (TRβPV mice). This TRβPV
mouse faithfully reproduces human RTH [11,13,14]. To study
the in vivo effects of T3 in the presence of normal TRβ, we
used a mouse model of pharmacologic hyperthyroidism by
treating the wild-type siblings with T3 (iT3 mice). This model
aided in the delineation of genes associated with the hyper-
thyroid and RTH phenotype. Gene-expression patterns were
analyzed in three T3 target tissues - cerebellum, heart and
WAT - previously shown to have marked variation in meta-
bolic patterns after T3 treatment.http://genomebiology.com/2004/5/5/R31 Genome Biology 2004,     Volume 5, Issue 5, Article R31       Miller et al. R31.11
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Several interesting observations emerged from our study.
First, we found that the normal physiologic effect of T3 on
specific tissues is predominantly downregulation of gene
expression. In the T3-treated mice, the majority of expression
outliers in the heart (71%) and WAT (76%) were repressed.
The same phenomenon has been observed in other mouse in
vivo  expression studies, albeit using less comprehensive
array technologies. Feng et al. [36] identified 55 outliers in
the livers of hypothyroid mice injected with T3; of these, 14
(25%) were upregulated and 41 (75%) were downregulated.
Similarly, in a mouse model of T3-induced involution of a thy-
rotrope tumor, Wood et al. [37] identified 47 T3-responsive
genes: seven (15%) were upregulated whereas 40 (85%) were
downregulated. Thus, taken together, these studies indicate
that T3 predominantly suppresses gene expression in respon-
sive tissues. As would be predicted, in the RTH model, the
majority of genes in the heart (63%) and, to a lesser extent in
the WAT (53%), were upregulated. Of the 25 genes in the
heart and 33 genes in WAT that showed opposite expression
patterns in RTH (PV) and iT3 mice, 84% and 79% in heart
and WAT, respectively, were repressed by T3 treatment and
induced in RTH. Together, these data suggest that certain
RTH (and perhaps hypothyroid) tissue phenotypes may be
due predominantly to the inappropriate induction of genes
normally repressed by T3. Using the number of differentially
expressed genes as a semi-quantitative measure of pharma-
codynamic effect, we found that the cerebellum is by far the
least responsive in both iT3 and RTH, whereas the heart is the
most responsive in iT3 (approximately fivefold more than
cerebellum and approximately twofold more than WAT;
Table 1) and the WAT is the most responsive in RTH (around
10-fold more than heart, while the cerebellum showed no
changes in gene expression greater than twofold; Table 1).
Category analysis of expression patterns in iT3 and RTH mice
shed light on the transcriptional consequences of the PV
mutant (Figure 2). Category A consists of genes for which the
T3-induced response was not affected by the expression of
PV, indicating that the responses of these genes to increased
T3 are likely to be exclusively mediated by TRα1. However, we
have recently demonstrated that PV can form inactive het-
erodimers with TRα1, thereby suppressing the transcrip-
tional activity of TRα1 [10]. This suggests the possibility that
genes in category A may, in some instances, be modulated by
TR-independent pathways: a notion supported by recent
studies demonstrating that T3 can act in alternate pathways
independent of TRs [38]. Categories B and C consist of T3-
response genes mediated by TRs, but their transcriptional
responses are altered by PV. In category B, the directionality
of response in iT3 and RTH is reversed. These genes may be
of particular importance in the phenotypic manifestations of
RTH. Notable examples are the TSHβ and the α-glycoprotein
common subunit genes that are repressed in the mouse pitu-
itary following T3 administration [39]. However, in the pitu-
itary of TRβPV/PV mice, the expression of the PV mutant leads
to the induction of these two genes, resulting in the highly ele-
vated serum TSH [11].
Genes in category C were responsive to T3 treatment yet
insensitive to hyperthyroid levels of T3 in the presence of PV.
These genes are not differentially expressed between
untreated euthyroid wild-type mice and TRβPV/PV littermates
and thus may reflect changes specific to pharmacologic
hyperthyroidism. Alternatively, these genes may be primary
targets of TRα1 and their expression levels in TRβPV/PV mice
mimic euthyroid levels as a result of partial transcriptional
interference by PV. Some of the interesting genes in this cat-
egory include cytochrome c oxidase, subunit VIII and Rous
sarcoma oncogene (Table 2).
One particularly interesting finding concerns the genes in cat-
egory D. These genes did not respond to T3 treatment, but
showed altered expression in the presence of PV. WAT had a
particularly high number of genes in this category (53% (116/
215) compared to heart (3%) (3/105)). The modulation of
these genes in RTH could arise from the systemic effects of T3
resistance. Alternatively, the transcriptional response of
these genes could be mediated by PV, either directly or indi-
rectly, in a T3-independent manner. For example, we have
previously shown that PV can heterodimerize with the 9-cis
retinoacid receptor, RXR [10]. Heterodimerization of a
mutant TRα with other nuclear receptors could simultane-
ously alter other hormone signaling pathways in RTH in a T3-
independent manner.
The experimental design of this study afforded a unique
opportunity to investigate the involvement of cellular path-
ways that may contribute to the pathophysiology of mutant
TRβ action in the intact animal. Through pattern analysis of
genes identified as differentially expressed in iT3 or TRβPV/PV
mice in one or more tissues, we identified several gene clus-
ters with clear functional associations that may have patho-
logical implications in thyroid hormone disease (Figure 1).
Then, on a tissue-by-tissue basis, we were able to focus on
expression patterns and pathways most relevant to the tissue
type.
The lipogenesis cluster in Figure 3 consists of six genes (Fasn,
Acly, Gpd1, Elovl6, Slc25a1 and the homolog of rat Acac) that
were repressed in both iT3 and RTH mice (category A genes;
Table 1). These genes are known to have important roles in
fatty-acid and lipid synthesis. This finding presumably
reflects the known function of T3 as a regulator of lipogenesis
and lipolysis in adipocytes [26] and, specifically, as a tran-
scriptional modulator of Fasn,  Acly  and  Gpd1  [40-42].
Whereas T3 is known to induce lipogenesis in the liver [26],
downregulation of fatty-acid synthase and acetyl-CoA carbox-
ylase genes was reported in brown adipose tissue of T3-
treated hypothyroid rats [24]. This is consistent with the
physiologic findings that hyperthyroid rats display dimin-
ished fatty-acid synthesis in brown and white adipose tissuesR31.12 Genome Biology 2004,     Volume 5, Issue 5, Article R31       Miller et al. http://genomebiology.com/2004/5/5/R31
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[26]. That all six of these genes were downregulated in the
WAT of both iT3 and RTH mice suggests that the T3-medi-
ated inhibition of lipogenesis in this tissue is independent of
TRβ and may be the main targets of TRα1 in this tissue. This
possibility is supported by the observations of multiple TR
transcriptional response elements in the promoters of both
Fas and Gpd1 [43,44] and the observation that mice hetero-
zygous for a TRα1 point mutation (resulting in a dominant-
negative TRα1 mutant with elevated T3 and T4) showed a
more than fourfold increase in body fat compared to wild-
type mice [45]. The suppression of these genes in both T3-
treated and TRβPV/PV  mice could represent an important
mechanism in the phenotype of body-fat reduction common
to both hyperthyroidism and RTH.
We identified in Figure 3 a small cluster of genes with similar
expression patterns that are composed of cell-cycle inhibitory
and apoptosis-promoting genes. Cdkn1a  (encoding p21, a
major cyclin-dependent kinase inhibitor that induces G1
arrest), APC (a negative regulator of Wnt-induced cell prolif-
eration), and Bnip3 (a potent promoter of apoptosis) are all
induced by T3 treatment in the cerebellum, heart and WAT.
The gene for the growth inhibitor Gadd45a is induced in the
heart of iT3 mice and the WAT of RTH mice, in a fashion sim-
ilar to that of Cdkn1a. Though the mitogenic activity of thy-
roid hormone has been documented in vitro [46,47], little is
known of the cellular mechanisms underlying the antiprolif-
erative [48,49] and apoptotic effects [50,51] of T3. Recently,
we and others have shown that T3 treatment of cultured cells
can induce expression of the p53  tumor suppressor gene
[19,52]. Several of the genes in this T3-inducible cluster are
known transcriptional targets of p53, including Gadd45a
[53], Cdkn1a [54] and APC [55], suggesting that a coordi-
nated transcriptional cassette supportive of growth arrest
induced by T3 is likely to be mediated directly and/or indi-
rectly by TRα1. The induction of an antiproliferative/tumor
suppressor pathway is also consistent with our previous find-
ings that the Wnt pathway is coordinately repressed by T3 in
rat pituitary cells [19]. v-erbA is a viral oncogene whose onco-
genic function is the inhibition of the thyroid hormone recep-
tor through a dominant-negative effect. These observations
support our hypothesis that a major mechanism for the trans-
forming function of v-erbA is its cellular inhibition of T3/
TRα1 effects, resulting in coordinate upregulation of onco-
genic pathways (that is, the Wnt signaling pathway), and
repression of antiproliferation and tumor suppressor signals
(for example, p53, Gadd45a, Cdkn1a).
Finally, we discovered an overall repression in the expression
of immune-related genes in iT3 and RTH mice (Figure 3). To
further understand the functions of these genes, we analyzed
the expression of all outlier genes from the Figure 3 dataset
with known roles in immune response or immune-cell biol-
ogy. The expression profiles of 28 genes meeting these crite-
ria are shown in Figure 4. Interestingly, all but six of these 28
genes showed reduced expression in the WAT of TRβPV/PV
mice, and half were repressed in the hearts of iT3 mice. That
these genes represent lineage-specific markers of a variety of
immune cells, and that they are consistently reduced in two
tissues (the heart (iT3) and WAT (RTH)), suggests that at
least a fraction of these genes may reflect a general lack of
lymphocytes in these tissues of hyperthyroid and RTH mice.
Indeed, it has been observed that hypothyroid mouse strains
have significantly reduced numbers of pro-B, pre-B, and B
cells, and treatment of these mice with T4 increases the
number of B-lineage cells [56]. In addition, increases in num-
bers of splenic and thymic T cells and splenic NK cells have
also been observed in mice treated long term with T3 [57].
Intriguingly, mouse primary adipocytes themselves are
known to be capable of expressing multiple chemokines and
inflammatory mediators [58]. As shown in Figure 4, we also
observed reduced expression of chemokines CCL22, CCL6
and CXCL13 (which together are chemotactic for B cells, T
cells, monocytes and macrophages) and induction of Socs5 (a
suppressor of cytokine signaling) in the WAT of RTH mice.
The repression of these genes could contribute to an attenua-
tion of lymphocytic residence in this tissue.
The heart is a major target of thyroid hormone action, and T3
has a direct effect on heart rate and contractile function. Both
TRα1 and TRβ are expressed in cardiac myocytes; however,
TRα1 is the predominant subtype, and recent reports have
suggested a primary role for TRα1 in mediating T3 effects in
the heart [10,59,60]. It has been hypothesized that, in cardiac
tissue from TRβPV/PV mice, the primary effects of the elevated
T3 would be mediated through heightened T3/TRα1 signal-
ing and that the expression response would be similar, if not
identical, to that found in the myocardium of wild-type mice
with induced hyperthyroidism by exogenous administration
of T3. Contrary to this hypothesis, we observed a large degree
of discordant cardiac gene expression when we compared the
responsive genes of T3-treated animals having wild-type
TRα1 and TRβ with those of TRβPV/PV mice with wild-type
TRα1 (Table 2). The hearts of T3-treated animals showed
expression of genes indicative of an altered workload. When
heart workload increases or decreases, there is a switch in
energy source from predominantly the oxidation of fatty acids
to the oxidation of glucose [61]. Three key regulators facilitate
this switch: malonyl-CoA decarboxylase (MCD), uncoupling
protein 3 (UCP3) and pyruvate dehydrogenase kinase 4
(PDK4). In our study, both MCD (which regulates β-oxidation
of long-chain fatty acids) and UCP3 (which uncouples the oxi-
d a t i v e  p h o s p h o r y l a t i o n  o f  A D P )  w e r e  u p r e g u l a t e d  a t  t h e
mRNA level in the hearts of T3-treated animals, with con-
commitant downregulation of all the genes of the lipogenesis
cluster (Figure 3). In contrast, the RTH heart did not show
induction of MCD or UCP3, but rather shows increased
mRNA levels for the lipogenic genes Fasn,  Elovl6  and
Slc25a1, suggesting a different metabolic signaling in the
RTH heart. Recently, Swanson et al. reported that the TRβPV/
PV mice, under euthyroid conditions, have decreased heart
rate and contractile function, demonstrating that despite ahttp://genomebiology.com/2004/5/5/R31 Genome Biology 2004,     Volume 5, Issue 5, Article R31       Miller et al. R31.13
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lower expression of TRβ as compared with TRα1 in the mouse
heart, the homozygous PV mutant can negatively interfere
with TRα1 signaling in this organ [62]. Our genomic results
are in agreement with these physiologic findings and provide
a glimpse at the gene-by-gene tissue response to T3 stress.
Conclusions
The clinical manifestations of RTH and hyperthyroidism are
well documented, and although the genetic cause of RTH is
known, the target-tissue transcriptional responses and
cellular pathways affected are far from being understood. In
our study we have used expression profiling to dissect the
molecular consequences of a dominant-negative TRβ
homozygous mutation in vivo, and in the process, develop a
better understanding of TRα1 effects in the whole animal. Our
results show that T3 primarily acts to repress gene expres-
sion, and that TRβ has a greater modulating effect in the heart
than originally thought. Moreover, we identified novel physi-
ologic candidates for more subtle T3 action such as changes in
immune-gene expression, and in the induction of antiprolif-
erative genes. Lastly, our analysis further confirms that the
relative levels of TR isoforms lead to dramatic differential
effects on gene expression. The results permit the identifica-
tion of genetic elements that contribute to downstream iso-
form effects in individual tissues [59,60].
Materials and methods
Mouse strains and treatment
The animal protocols used in the present study have been
approved by the National Cancer Institute Animal Care and
Use Committee. The TRβPV mice contain a cytosine insertion
in exon 10 of the TRβ1 gene at nucleotide position 1,642 of the
TRβ1 cDNA. This mutation leads to a frameshift of the car-
boxy-terminal 14 amino acids of TRβ1 [11,12]. TRβPV mice
were prepared via homologous recombination and main-
tained on a mixed background of 129/Sv × C57BL/6J [11].
TRβ+/+ and TRβPV/PV male siblings at 8-10 weeks of age were
used in this study. Another group of wild-type (TRβ+/+) male
Treeview visualization of iT3- and PV-responsive immunity/lymphocyte-related genes Figure 4
Treeview visualization of iT3- and PV-responsive immunity/lymphocyte-related genes. Higher and lower transcript levels in T3-treated animals (iT3) or 
RTH mice (PV) are indicated by arrows (as relative to iT3 control or wild-type mice, respectively). IMAGE clone IDs and UniGene names are given; 
asterisks (*) indicate immune cell-specific genes.
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littermates of TRβPV/PV received daily intraperitoneal injec-
tions of T3 (5 µg/mouse) or the same volume of vehicle (phos-
phate-buffered saline) for 7 days. On the eighth day the
animals were sacrificed by CO2 exposure and tissues (cerebel-
lum, heart and white adipose) were harvested.
RNA preparation
Total RNAs were extracted from liquid nitrogen-frozen tissue
specimens using Trizol reagent according to the manufac-
turer's instructions (Gibco-BRL). To minimize differences in
gene expression owing to inter-animal variability, for each
tissue and animal category, 5 µg of total RNA from four ani-
mals were pooled before RNA amplification. RNA
amplification and quality assessment was carried out as pre-
viously described [64].
Microarray design and manufacture
The mouse cDNA microarrays contained 11,520 sequences
derived from various sequence-verified clone collections
including the Incyte GEM1 mouse clone set (8,700; Incyte),
the Research Genetics mouse sequence-verified set (2,600;
Research Genetics,), and a private collection of 200 mouse
ESTs (a gift from Lothar Heninghausen, NCI, Bethesda, MD).
All arrays were manufactured at the NCI Microarray Facility
at the Advanced Technology Center, Gaithersburg, MD.
Arrays were printed using an OmniGrid microarrayer
(GeneMachines) on poly-L-lysine-coated-glass according to
Eisen and Brown [63].
Microarray hybridization and scanning
For each experimental comparison, duplicate microarray
hybridizations were performed according to a reciprocal
strategy termed dye-swapping. In this approach, the Cy3 and
Cy5 labeling scheme for the two arrays are reversed such that
a true differentially expressed gene having a ratio of 2.0 (that
is, a 2-fold red (Cy5-biased) spot) on one array, for example,
would have a reciprocal ratio of approximately 0.5 (that is, a
2-fold green (Cy3-biased) spot) on the other array. Notably,
this form of experimental replication is more rigorous than
conventional duplication (that is, true replicates using the
same labeling scheme) as it takes into account a recognized
form of experimental noise in microarray technology charac-
terized by the reproducible bias of one fluorophore over the
other at low signal intensity features (termed dye bias). Three
micrograms amplified RNA were used to generate Cy3- or
Cy5-labeled cDNA for each array hybridization. cDNA labe-
ling reaction and array hybridization were carried out essen-
tially as described [63]. Microarrays were scanned on a
GenePix 4000A microarray scanner (Axon Instruments) to
generate 16-bit TIFF images of Cy3 and Cy5 signal intensities.
The images were analyzed using GenePix Pro 3.0 microarray
analysis software to measure fluorescence signals and format
data for database deposition.
Outlier selection and data analysis
All array data were deposited in the NCI-CIT microarray
database [65] where Cy3 and Cy5 signals were median nor-
malized and expression ratios (Cy5/Cy3) were calculated. The
following selection criteria were applied. All spots having a
mean signal (after background subtraction) less than twice
that of background in both Cy3 and Cy5 channels were sys-
tematically excluded from the dataset to eliminate measure-
ments based on poorly detected features. The data were also
filtered to exclude spots flagged as missing or corrupt in one
or both arrays of a dye-swap pair. Remaining outliers were
then selected by the 2.0r criterion, whereby an expression
ratio must demonstrate a twofold or greater change on each
array of a pair of reciprocal dye-swap hybridizations. We also
demanded that the ratios must be in opposite expression
directions (that is, > 2.0 on one array, and < 0.5 on the other)
to exclude 'false-positive outliers' that showed a reproducible
bias towards either red or green fluorescence and thus failed
to reciprocate in the dye-swap array pairs. We next calculated
the average expression ratio from the dye-swap pairs (after
taking the reciprocal ratio from one of the two arrays) and
report the average expression ratios in all analyses herein. For
reporting genes by name, IMAGE clone IDs corresponding to
the microarray probe sequences were used to extract Uni-
Gene Cluster IDs and names (UniGene Build 129). For genes
represented by multiple probes on the array, a single probe
was used (that is, the probe that showed the greatest tran-
scriptional variation) to report the expression ratio so as to
prevent gene number biasing owing to redundant probes.
RT-PCR analysis
The expression of selected genes was also analyzed by quanti-
tative RT-PCR using the following pairs of primers:
APC forward primer 5'-GCTGACATCTGTGCTGTGGATGG-
3';
APC reverse primer 5'-TCCTTAAAGCTGCTGCACTTCCC-3';
somatostatin forward primer 5'-TGCATCGTCCT-
GGCTTTGG-3';
somatostatin reverse primer 5'-GAGTTAAGGAAGAGATAT-
GGG-3';
tenascin C forward primer 5'-TTCGTGTGTTCGCCATCTTG-
3';
tenascin C reverse primer 5'-GTGTGAGGTCGATGGTGGT-
3';
carbonic anhydrase 4 forward primer 5'-TCACTGCTAG-
GACAAAGGTG-3';
carbonic anhydrase 4 reverse primer 5'-AGAGGTTGAAT-
GGGGTTTGG-3';http://genomebiology.com/2004/5/5/R31 Genome Biology 2004,     Volume 5, Issue 5, Article R31       Miller et al. R31.15
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lysyl oxidase forward primer 5'-CTACATCCAGGCTTCCACG-
3';
lysyl oxidase reverse primer 5'-TCTCCTCTGTGTGTT-
GGCAT-3';
enolase 3β, muscle forward primer 5'-TCAAGGGTTA-
CACTCTGCCT-3';
enolase 3β, muscle reverse primer 5'-TCGTTCAC-
CCACACAAGGAA-3';
creatine kinase, muscle forward primer 5'-TTCCTTGTGT-
GGGTGAACGA-3';
creatine kinase, muscle reverse primer 5'-TTTTCCAGCTTCT-
TCTCCATC-3';
GAPDH forward primer 5'-ACATCATCCCTGCATCCACT-3';
GAPDH reverse primer 5'-GTCCTCAGTGAGCCCAAG-3'.
Total RNA (5 µg) prepared as described above was used in the
quantitative RT-PCR reaction. cDNA was prepared by
SuperScript II reverse transcriptase I (Invitrogen) in the pres-
ence of poly(dT) primer. Preliminary experiments were
carried out to define the conditions under which the amplifi-
cation by PCR was in the linear range. The final conditions
used for each were: 94°C for 30 sec, 60°C for 30 sec, 72°C for
30 sec followed by 72°C for 2 min. A total of 26 cycles were
used for the amplification of APC, carbonic anhydrase 4, lysyl
oxidase and somatostatin cDNA. A total of 32 cycles were
used for the amplification of tenascin C, enolase 3β (muscle)
and creatine kinase (muscle) cDNA. The PCR products were
analyzed by 2% agarose gel electrophoresis and detected by
ethidium bromide staining. The intensities of the bands were
quantified by Eagle Eye (Stratagene). The expression of
GAPDH was determined similarly (22 cycles) as an internal
control. The band intensities of the quest genes were normal-
ized against the control. The data are expressed as mean value
± SEM (n  = 3 independent determinations). Differences
between groups were examined for statistical significance
using Student's t-test.  p  < 0.05 is considered statistically
significant.
Additional data files
The following additional data files are available with the
online version of this article and also at the authors' website
[66]: an Excel table (Additional data file 1) of all redundant
microarray probes and their average expression ratio meas-
urements; an Excel file (Additional data file 2) containing a
comprehensive filtered gene list of average expression ratios;
a figure (Additional data file 3) showing a hierarchical clus-
tergram of 2.0r outlier genes with full annotation; a Word
table (Additional data file 4) listing the responsive genes
known to be modulated by T3; an Excel table (Additional data
file 5) listing genes differentially expressed in the heart of iT3
and/or RTH mice, while another table (Additional data file 6)
lists genes differentially expressed in the white adipose tissue
(WAT) of iT3 and/or RTH mice. Also provided is an Excel file
(Additional data file 7) listing genes that are differentially
expressed in the cerebellum of iT3 and/or RTH mice; and,
finally, a zipped text file (Additional data file 8) containing
the raw data.
Additional data file 1 An Excel table of all redundant microarray probes and their aver- age expression ratio measurements An Excel table of all redundant microarray probes and their aver- age expression ratio measurements Click here for additional data file Additional data file 2 An Excel file containing a comprehensive filtered gene list of aver- age expression ratios An Excel file containing a comprehensive filtered gene list of aver- age expression ratios Click here for additional data file Additional data file 3 A figure showing a hierarchical clustergram of 2.0r outlier genes  with full annotation A figure showing a hierarchical clustergram of 2.0r outlier genes  with full annotation Click here for additional data file Additional data file 4 A Word table listing the responsive genes known to be modulated  by T3 A Word table listing the responsive genes known to be modulated  by T3 Click here for additional data file Additional data file 5 An Excel table listing genes differentially expressed in the heart of  iT3 and/or RTH mice An Excel table listing genes differentially expressed in the heart of  iT3 and/or RTH mice Click here for additional data file Additional data file 6 An Excel table lists genes differentially expressed in the white adi- pose tissue (WAT) of iT3 and/or RTH mice An Excel table lists genes differentially expressed in the white adi- pose tissue (WAT) of iT3 and/or RTH mice Click here for additional data file Additional data file 7 An Excel file listing genes that are differentially expressed in the  cerebellum of iT3 and/or RTH mice An Excel file listing genes that are differentially expressed in the  cerebellum of iT3 and/or RTH mice Click here for additional data file Additional data file 8 A zipped text file containing the raw data A zipped text file containing the raw data Click here for additional data file
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